Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb 18:6:41.
doi: 10.3389/fgene.2015.00041. eCollection 2015.

Use of pharmacogenomics in pediatric renal transplant recipients

Mara Medeiros  1 , Gilberto Castañeda-Hernández  2 , Colin J D Ross  3 , Bruce C Carleton  3
Affiliations
Review

Use of pharmacogenomics in pediatric renal transplant recipients

Mara Medeiros et al. Front Genet. .

Abstract

Transplant recipients receive potent immunosuppressive drugs in order to prevent graft rejection. Therapeutic drug monitoring is the current approach to guide the dosing of calcineurin inhibitors, mammalian target of rapamycin inhibitors (mTORi) and mofetil mycophenolate. Target concentrations used in pediatric patients are extrapolated from adult studies. Gene polymorphisms in metabolizing enzymes and drug transporters such as cytochromes CYP3A4 and CYP3A5, UDP-glucuronosyl transferase, and P-glycoprotein are known to influence the pharmacokinetics and dose requirements of immunosuppressants. The implications of pharmacogenomics in this patient population is discussed. Genetic information can help with achieving target concentrations in the early post-transplant period, avoiding adverse drug reactions and drug-drug interactions. Evidence about genetic studies and transplant outcomes is revised.

Keywords: GWAS; acute rejection; adverse reactions; drug metabolism; genotype; graft survival; immunosuppression; pharmacogenomics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Ali A. A., Charoo N. A., Abdallah D. B. (2014). Pediatric drug development: formulation considerations. Drug. Dev. Ind. Pharm. 40, 1283–1299. 10.3109/03639045.2013.850713 - DOI - PubMed
    1. Bansal S. B., Saxena V., Pokhariyal S., Gupta P., Kher V., Ahlawat R., et al. . (2011). Comparison of azathioprine with mycophenolate mofetil in a living donor kidney transplant programme. Indian J. Nephrol. 21, 258–263. 10.4103/0971-4065.85483 - DOI - PMC - PubMed
    1. Brugnoni D., Airo P., Graf D., Marconi M., Molinari C., Braga D., et al. . (1996). Ontogeny of CD40L [corrected] expression by activated peripheral blood lymphocytes in humans. Immunol. Lett. 49, 27–30. 10.1016/0165-2478(95)02468-9 - DOI - PubMed
    1. Chen Z., Bouamar R., Van Schaik R. H., De Fijter J. W., Hartmann A., Zeier M., et al. . (2014). Genetic polymorphisms in IL-2, IL-10, TGF-beta1, and IL-2RB and acute rejection in renal transplant patients. Clin. Transplant. 28, 649–655. 10.1111/ctr.12346 - DOI - PubMed
    1. de Jonge H., Elens L., de Loor H., van Schaik R. H., Kuypers D. R. (2014). The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. Pharmacogenomics J. [Epub ahead of print]. 10.1038/tpj.2014.49 - DOI - PubMed

LinkOut - more resources